Unraveling Protein Misfolding Diseases Using Model Systems

References

• Van Dam D , De DeynPP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br. J. Pharmacol.164(4), 1285–1300 (2011).
   PubMed Web of Science ®Google Scholar
• Levin ED , RoseJE, McgurkSR, ButcherLL. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav. Neural Biol.53(1), 103–112 (1990).
   PubMedGoogle Scholar
• Yamada M , ChibaT, SasabeJet al. Implanted cannula-mediated repetitive administration of Aβ25–35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav. Brain Res.164(2), 139–146 (2005).
   PubMed Web of Science ®Google Scholar
• Roberts TJ . 3-Nitropropionic acid model of metabolic stress. Methods Mol. Med.104, 203–220 (2005).
   PubMedGoogle Scholar
• Sanberg PR , CalderonSF, GiordanoM, TewJM, NormanAB. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp. Neurol.105(1), 45–53 (1989).
   PubMed Web of Science ®Google Scholar
• Ungerstedt U . 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol.5(1), 107–110 (1968).
   PubMed Web of Science ®Google Scholar
• Prikhojan A , BrannanT, YahrM. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. J. Neural Transmission107(10), 1159–1164 (2000).
   PubMed Web of Science ®Google Scholar
• Philipson O , LordA, GumucioA, O'callaghanP, LannfeltL, NilssonLN. Animal models of amyloid-β-related pathologies in Alzheimer's disease. FEBS J.277(6), 1389–1409 (2010).
   PubMed Web of Science ®Google Scholar
• Wirak D , BayneyR, RamabhadranTet al. Age-associated inclusions in normal and transgenic mouse brain. Science255, 1445 (1992).
   PubMedGoogle Scholar
• Lamb BT , SisodiaSS, LawlerAMet al. Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice. Nat. Genet.5(1), 22–30 (1993).
   PubMed Web of Science ®Google Scholar
• Irizarry MC , SorianoF, McnamaraMet al. Aβ deposition is associated with neurophil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci.17(18), 7053–7059 (1997).
   PubMed Web of Science ®Google Scholar
• Masliah E , SiskA, MalloryM, GamesD. Neurofibrillary pathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein. J. Neuropathol. Exp. Neurol.60(4), 357–368 (2001).
   PubMed Web of Science ®Google Scholar
• Ona VO , LiM, VonsattelJPGet al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature399(6733), 263–267 (1999).
   PubMed Web of Science ®Google Scholar
• Chesselet M-F . In vivo α-synuclein overexpression in rodents: a useful model of Parkinson's disease?Exp. Neurol.209(1), 22–27 (2008).
   PubMed Web of Science ®Google Scholar
• Li X , PatelJC, WangJet al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci.30(5), 1788–1797 (2010).
   PubMed Web of Science ®Google Scholar
• Greeve I , KretzschmarD, TschäpeJ-Aet al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci.24(16), 3899–3906 (2004).
   PubMed Web of Science ®Google Scholar
• Finelli A , KelkarA, SongH-J, YangH, KonsolakiM. A model for studying Alzheimer's Aβ42-induced toxicity in Drosophila melanogaster. Mol. Cell. Neurosci.26(3), 365–375 (2004).
   PubMed Web of Science ®Google Scholar
• Iijima K , LiuH-P, ChiangA-S, HearnSA, KonsolakiM, ZhongY. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl Acad. Sci. USA101(17), 6623–6628 (2004).
   PubMed Web of Science ®Google Scholar
• Crowther D , KinghornK, MirandaEet al. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience132(1), 123–135 (2005).
   PubMed Web of Science ®Google Scholar
• Whitworth AJ , WesPD, PallanckLJ. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today11(3), 119–126 (2006).
   PubMed Web of Science ®Google Scholar
• Pendleton RG , ParvezF, SayedM, HillmanR. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J. Pharmacol. Exp. Ther.300(1), 91–96 (2002).
   PubMed Web of Science ®Google Scholar
• Lee W-CM , YoshiharaM, LittletonJT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl Acad. Sci. USA101(9), 3224–3229 (2004).
   PubMed Web of Science ®Google Scholar
• Pallos J , BodaiL, LukacsovichTet al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet.17(23), 3767–3775 (2008).
   PubMed Web of Science ®Google Scholar
• Agrawal N , PallosJ, SlepkoNet al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA102(10), 3777–3781 (2005).
   PubMed Web of Science ®Google Scholar
• Wolfgang WJ , MillerTW, WebsterJMet al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl Acad. Sci. USA102(32), 11563–11568 (2005).
   PubMed Web of Science ®Google Scholar
• Warrick JM , ChanHE, Gray-BoardGL, ChaiY, PaulsonHL, BoniniNM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet.23(4), 425–428 (1999).
   PubMed Web of Science ®Google Scholar
• Auluck PK , ChanHE, TrojanowskiJQ, LeeVM-Y, BoniniNM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science295(5556), 865–868 (2002).
   PubMed Web of Science ®Google Scholar
• Muchowski PJ , WackerJL. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci.6(1), 11–22 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson GR , Wiedau-PazosM, SangT-Ket al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron34(4), 509–519 (2002).
   PubMed Web of Science ®Google Scholar
• Zhong H , ZouH, SemenovMVet al. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol. BioSyst.5(11), 1356–1360 (2009).
   PubMedGoogle Scholar
• Zou H , ZhouL, LiYet al. Benzo-[ε]-isoindole-1, 3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J. Med. Chem.53(3), 994–1003 (2009).
   Web of Science ®Google Scholar
• Anichtchik OV , KaslinJ, PeitsaroN, ScheininM, PanulaP. Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J. Neurochem.88(2), 443–453 (2004).
   PubMed Web of Science ®Google Scholar
• Bretaud S , LeeS, GuoS. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol. Teratol.26(6), 857–864 (2004).
   PubMed Web of Science ®Google Scholar
• Flinn L , MortiboysH, VolkmannK, KösterRW, InghamPW, BandmannO. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain132(6), 1613–1623 (2009).
   PubMedGoogle Scholar
• Markaki M , TavernarakisN. Modeling human diseases in Caenorhabditis elegans. Biotechnol. J.5(12), 1261–1276 (2010).
   PubMed Web of Science ®Google Scholar
• Haldimann P , MurisetM, VighL, GoloubinoffP. The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans. J. Biol. Chem.286(21), 18784–18794 (2011).
   PubMed Web of Science ®Google Scholar
• Gohil VM , OffnerN, WalkerJAet al. Meclizine is neuroprotective in models of Huntington's disease. Hum. Mol. Genet.20(2), 294–300 (2011).
   PubMed Web of Science ®Google Scholar
• Daigle I , LiC. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc. Natl Acad. Sci. USA90(24), 12045–12049 (1993).
   PubMed Web of Science ®Google Scholar
• Ewald CY , RapsDA, LiC. APL-1, the Alzheimer's amyloid precursor protein in Caenorhabditis elegans, modulates multiple metabolic pathways throughout development. Genetics191(2), 493–507 (2012).
   PubMed Web of Science ®Google Scholar
• Mccormick AV , WheelerJM, GuthrieCR, LiachkoNF, KraemerBC. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol. Psychiatry73(5), 464–471 (2013).
   PubMed Web of Science ®Google Scholar
• Munoz-Lobato F , Rodriguez-PaleroMJ, Naranjo-GalindoFJet al. Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases. Antioxid. Redox Signal.20(2), 217–235 (2014).
   PubMed Web of Science ®Google Scholar
• Li J , HuangKX, LeWD. Establishing a novel C. elegans model to investigate the role of autophagy in amyotrophic lateral sclerosis. Acta Pharmacol. Sin.34(5), 644–650 (2013).
   PubMed Web of Science ®Google Scholar
• Vaccaro A , PattenSA, CiuraSet al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS ONE7(7), e42117 (2012).
   PubMed Web of Science ®Google Scholar
• Outeiro TF , MuchowskiPJ. Molecular genetics approaches in yeast to study amyloid diseases. J. Mol. Neurosci.23(1–2), 49–59 (2004).
   PubMed Web of Science ®Google Scholar
• Heinicke S , LivstoneMS, LuCet al. The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. PLoS ONE2(8), e766 (2007).
   PubMed Web of Science ®Google Scholar
• Pimentel C , Batista-NascimentoL, Rodrigues-PousadaC, MenezesRA. Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxidat. Med. Cell. Longevity 2012:132146, (2012).
   PubMed Web of Science ®Google Scholar
• Bastow EL , GourlayCW, TuiteMF. Using yeast models to probe the molecular basis of amyotrophic lateral sclerosis. Biochem. Soc. Trans.39(5), 1482–1487 (2011).
   PubMedGoogle Scholar
• Winzeler EA , ShoemakerDD, AstromoffAet al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science285(5429), 901–906 (1999).
   PubMed Web of Science ®Google Scholar
• Willingham S , OuteiroTF, DevitMJ, LindquistSL, MuchowskiPJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or α-synuclein. Science302(5651), 1769–1772 (2003).
   PubMed Web of Science ®Google Scholar
• Giorgini F , GuidettiP, NguyenQ, BennettSC, MuchowskiPJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet.37(5), 526–531 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarcz R . The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol.4(1), 12–17 (2004).
   PubMed Web of Science ®Google Scholar
• Hu Y , LiuL, KmiecEB. Reduction of Htt inclusion formation in strains of Saccharomyces cerevisiae deficient in certain DNA repair functions: a statistical analysis of phenotype. Exp. Cell Res.291(1), 46–55 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper AA , GitlerAD, CashikarAet al. α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science313(5785), 324–328 (2006).
   PubMed Web of Science ®Google Scholar
• Soper JH , RoyS, StieberAet al. α-synuclein–induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell19(3), 1093–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Couthouis J , HartMP, ShorterJet al. A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl Acad. Sci. USA108(52), 20881–20890 (2011).
   PubMed Web of Science ®Google Scholar
• Outeiro TF , GiorginiF. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol. J.1(3), 258–269 (2006).
   PubMedGoogle Scholar
• Zhang X , SmithDL, MeriinABet al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl Acad. Sci. USA102(3), 892–897 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE , DuennwaldM, MarkovicPet al. Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet.15(18), 2743–2751 (2006).
   PubMed Web of Science ®Google Scholar
• Khurana V , LindquistS. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?Nat. Rev Neurosci11(6), 436–449 (2010).
   PubMed Web of Science ®Google Scholar
• Tardiff DF , JuiNT, KhuranaVet al. Yeast reveal a “druggable” Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science342(6161), 979–983 (2013).
   PubMed Web of Science ®Google Scholar
• Chung CY , KhuranaV, AuluckPKet al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science342(6161), 983–987 (2013).
   PubMed Web of Science ®Google Scholar
• Carrio M , CorcheroJ, VillaverdeA. Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. FEMS Microbiol. Lett.169(1), 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Morell M , BravoR, EspargaróAet al. Inclusion bodies: specificity in their aggregation process and amyloid-like structure. Biochim. Biophys. Acta Mol. Cell Res.1783(10), 1815–1825 (2008).
   PubMed Web of Science ®Google Scholar
• Carrió M , González-MontalbánN, VeraA, VillaverdeA, VenturaS. Amyloid-like properties of bacterial inclusion bodies. J. Mol. Biol.347(5), 1025–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Kim W , KimY, MinJ, KimDJ, ChangY-T, HechtMH. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol.1(7), 461–469 (2006).
   PubMed Web of Science ®Google Scholar
• Mckoy AF , ChenJ, SchupbachT, HechtMH. A novel inhibitor of amyloid β (Aβ) peptide aggregation form high throughput screening to efficacy in an animal model of Alzheimer disease. J. Biol. Chem.287(46), 38992–39000 (2012).
   PubMed Web of Science ®Google Scholar